Moderna announces positive results for Omicron vaccine / Photo: Joseph Prezioso - AFP
NYSE - LSE
| SCS | -0.56% | 16.14 | $ | |
| GSK | -0.33% | 48.41 | $ | |
| NGG | -0.66% | 75.41 | $ | |
| CMSD | -0.3% | 23.25 | $ | |
| BCC | -1.66% | 73.05 | $ | |
| RBGPF | 0% | 78.35 | $ | |
| BP | -3.91% | 35.83 | $ | |
| BTI | -1.81% | 57.01 | $ | |
| CMSC | -0.21% | 23.43 | $ | |
| AZN | 0.17% | 90.18 | $ | |
| BCE | 1.4% | 23.55 | $ | |
| VOD | -1.31% | 12.47 | $ | |
| RELX | -0.55% | 40.32 | $ | |
| RYCEF | -0.34% | 14.62 | $ | |
| RIO | -0.92% | 73.06 | $ | |
| JRI | 0.29% | 13.79 | $ |
Moderna announces positive results for Omicron vaccine
US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.
This so-called "bivalent" vaccine was tested in a trial of more 850 adults, who had all received their first three doses of Moderna's original Spikevax vaccine.
Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.
Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies -- Y-shaped immune system proteins that block the virus -- against Omicron.
On average, these levels were around 75 percent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.
"We are thrilled," said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.
"We want to be as ready as early as August for shipping," he told investors in a call.
Stephen Hoge, the company's president, did concede that antibody levels would be lower against Omicron's sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.
The company doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.
A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.
O.Osman--CdE
